Rectify Pharmaceuticals Launches with $100 Million Series A Financing from Atlas Venture, Omega Funds, Forbion, and Longwood Fund
Summary
Previously, Dr. Moore was a founding scientist at Vertex Pharmaceuticals Incorporated, where he pioneered efforts to treat people with cystic fibrosis by developing precision therapies targeting CFTR, a member of the ABC transporter family. “The seasoned management team at Rectify leaves us feeling confident in the future growth of this promising company, and we look forward to supporting them on their mission to deliver life-changing therapies for patients with rare genetic diseases.” In addition to Dr. Devraj and Dr. Moore, Rectify Pharma’s leadership team includes Tracey Dawson, Ph.D., Chief Operating Officer, Janeta Popovici-Muller, Ph.D., Senior Vice President, Head of Drug Discovery, and Alastair Garfield, Ph.D., Senior Vice President, Head of Biology. Rectify’s Board includes successful biotechnology company builders and its scientific advisors are experienced life science innovators with extensive expertise in drug discovery, structural biology, and liver diseases. • Richard Thompson, BM BCh, DM, Professor of Molecular Hepatology, School of Immunology & Microbial Sciences at King’s College London Rectify is developing disease-modifying precision therapies that restore ABC transporter function to address the underlying cause of serious genetic diseases. For more information, please visit: www.forbion.com Longwood Fund is a leading venture capital firm dedicated to creating and investing in novel healthcare companies that develop important treatments to help patients while targeting significant value for investors.